Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 3Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 52Thoracic 21Genitourinary 13Gastrointestinal 11CNS 9Lymphoid 6Breast 6Gynecologic 5Tumor-Agnostic 4Other hematologic neoplasm 4Sarcoma 3Plasma cell 3Head & Neck 3Other solid neoplasm 2Myeloid 2NET 1Endocrine 1Classical hematology 1

Conditions

Neuroendocrine Tumors 1Carcinoid Tumor 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 3lanreotide 3Erlotinib Hydrochloride 3surufatinib 2gallium Ga 68 dotatate 2dactolisib 2Sunitinib 2Octreotide 2Magnetic Resonance Spectroscopy 2Filgrastim 2Capecitabine 2trifluridine tipiracil drug combination 1tislelizumab 1telotristat ethyl 1telotristat 1pertuzumab 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1fosbretabulin 1folfirinox 1famitinib 1entinostat 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1alectinib 1Temozolomide 1Surveys and Questionnaires 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Ipilimumab × NET × Clear all
NCT03420521 2024-01-09

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated
9 enrolled 17 charts
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡